Transradial versus transfemoral arterial access in DEB-TACE for hepatocellular carcinoma.
JournalJournal of clinical imaging science
MetadataShow full item record
AbstractObjectives: Transradial access has become increasingly popular in body interventional procedures but has not been ubiquitously adapted. This retrospective study compares the efficacy of this approach versus transfemoral access in hepatocellular carcinoma (HCC) patients who underwent drug-eluting bead transarterial chemoembolization (DEB-TACE). Materials and methods: A total of 130 HCC patients underwent 146 DEB-TACE procedures within our institution from June 2015 to May 2020. About 90 and 56 procedures were logged for the transradial and transfemoral cohorts, respectively. Peak skin dose, fluoroscopy time, administered contrast volume, total procedure time, and equipment cost data for each procedure were reviewed to evaluate for statistical differences between the two groups. Results: All 146 cases were technically successful without major complications or access failures in either group. No statistical differences were present between the two access groups in regards to peak skin dose or fluoroscopy time. Transradial access recorded a significantly higher contrast volume (P < 0.05), and a significantly longer procedural time than transfemoral access (P < 0.01). However, transradial access also displayed a significantly lower procedural equipment cost (P < 0.01) between the two groups. Conclusion: Transradial DEB-TACE has similar trends to transfemoral DEB-TACE in several pertinent radiation parameters and is also significantly more cost-efficacious. The results of this investigation suggest the consideration of transradial access whenever viable as an alternative to transfemoral access in the DEB-TACE treatment of HCC patients.
Rights/Terms© 2022 Published by Scientific Scholar on behalf of Journal of Clinical Imaging Science.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/19835
- Transradial versus transfemoral arterial access in Yttrium-90 microspheres radioembolization for hepatocellular carcinoma.
- Authors: Ghosh A, Zhang J, Akhter NM
- Issue date: 2022
- Transradial versus transfemoral access without closure device for transarterial chemoembolization in patients with hepatocellular carcinoma: a randomized trial.
- Authors: Zhang X, Luo Y, Tsauo J, Zhao H, Gong T, Li J, Li Y, Zeng H, Sun W, Li X
- Issue date: 2022 Oct
- Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
- Authors: Zhang L, Sun JH, Ji JS, Zhong BY, Zhou GH, Song JJ, Hou ZH, Huang P, Zhang S, Li Z, Zhu XL, Ni CF
- Issue date: 2021 Oct
- Drug-eluting bead transarterial chemoembolization (TACE) exhibits superior efficacy and equal tolerance to conventional TACE in hepatocellular carcinoma patients with conventional TACE history.
- Authors: Tang J, Huang Z, Xu J, Lv Q, Wang P
- Issue date: 2022 Mar
- CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
- Authors: Wu B, Zhou J, Ling G, Zhu D, Long Q
- Issue date: 2018 Mar 27